Background {#Sec1}
==========

Depression is recognized as an important public health issue. By the year 2015 it affected around 4.4% of the population \[[@CR1]\], and by the year 2016 it was responsible for approximately 6.75% of years lived with disability in adults worldwide \[[@CR2]\]. Different actions are needed to improve the care of people suffering from depression, such as the development and implementation of adequate clinical practice guidelines (CPGs).

CPGs are classically defined as a set of "systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances" \[[@CR3]\]. CPGs can help to close gaps between evidence and policy, issuing recommendations in favor of the use of effective interventions and against the use of futile interventions \[[@CR4]\]; CPGs are needed to establish reliable recommendations achieved through a clear methodology \[[@CR5]\]. However, the methodology used for CPGs development is usually poorly defined and varies widely in content and quality between and within developing institutions \[[@CR6]\], which may lead to inconsistency between recommendations. Accordingly, a study that compared recommendations from 23 CPGs published between 2007 and 2017 found high inconsistency in recommendations for second and third-line of pharmacological treatment of depression \[[@CR7]\].

It is of great importance that stakeholders and mental health professionals are aware of the characteristics and quality of currently used CPGs for depression. The quality of the CPGs should be taken into account when interpreting and putting in practice recommendations issued in these CPGs. However, to our knowledge, only one study has assessed the quality of CPGs for depression and anxiety in children and youth \[[@CR8]\], and we have not found studies that have described the quality of CPGs for depression in adults. Thus, the aim of this study was to describe the characteristics and quality of CPGs for depression in adults.

Methods {#Sec2}
=======

We performed a scoping review of CPGs for depression in adults published in the last 5 years and evaluated characteristics regarding scope, methods used to reach recommendations, and grading the strength of recommendations. We also assessed the quality of each CPG. The PRISMA guidelines for scoping reviews (PRISMA-ScR) were used to secure adequate reporting and to guarantee the replicability of the study \[[@CR9]\].

A scoping review is "a form of knowledge synthesis, which incorporate a range of study designs to comprehensively summarize and synthesize evidence with the aim of informing practice, programs, and policy and providing direction to future research priorities" \[[@CR10]\]. It is similar to a systematic review, but it mainly differs on the objective they pursue. While a systematic review aims to find an answer to a well-defined question, a scoping review can be used identify, map and discuss certain characteristics in papers or studies \[[@CR11]\]. Given that our aim was to identify CPG and their characteristics, we decided to use the later.

Eligibility criteria {#Sec3}
--------------------

We included all CPGs, defined as a document that aimed to state recommendations, that fulfilled the following criteria: assessed screening, diagnosis or management of depression in adults; were published or totally/partially updated in the last 5 years (January 2014- May 2018); full-text were available in English or Spanish; and used systematic reviews of the evidence to guide their recommendations. We decided to include only CPGs based on systematic reviews, based on the current CPG definition which states that they should be designed based on a systematic review of the evidence \[[@CR12]\].

We excluded those CPGs that assessed specific types of depression such as bipolar or psychotic depression, or specific types of populations such as depression in patients with cancer or in older people after a stroke.

Search strategy {#Sec4}
---------------

We performed a comprehensive search in eighteen databases. Our search strategy included terms related to depression and guidelines/practice guidelines. Searchers were performed by two independent researchers (JHZT and DVZ), and the last update was run in June 2018 (see Additional file [1](#MOESM1){ref-type="media"}).

Study selection {#Sec5}
---------------

Two independent researchers (JHZT and DVZ) evaluated if the CPGs met the eligibility criteria for inclusion. When there were discrepancies, a consensus was reached after debating them among all the authors.

Data extraction {#Sec6}
---------------

The following characteristics were extracted from the CPGs: authors; year of publication; country; involvement of patients or their representatives in the CPG development process; methodology used to reach recommendations; methodology used for grading the strength of recommendations; usage of minimally important difference (MID) when evaluating the effect of interventions; and the number of recommendations and good clinical practice (GCP).

We defined a recommendation as "all the statements in favor or against an intervention based on systematic reviews of the evidence, which typically include a formal assessment of the benefits and drawbacks of available treatment options" \[[@CR13]\]. All the statements that synthetize opinions from an organized group of experts (expert consensus) and aim to describe "customary and expected care to be offered to patients" in situations where little to no evidence is available were considered as GCP \[[@CR13]\].

We defined MID as a measure of the "smallest change in patient-reported outcomes of interest that patients perceive as important" \[[@CR14]\].

Quality appraisal {#Sec7}
-----------------

To assess the quality of CPGs we used the Appraisal of Guidelines Research and Evaluation II (AGREE-II), which has 23 items distributed in six domains (scope and purpose, stakeholder involvement, rigor of development, clarity and presentation, applicability, and editorial independence). Each guideline was rated by two researchers. When a difference in two or more points in each item was found, the item was discussed to get to a consensus. Otherwise, we used the mean of the two raters for each item. Lastly, we followed the AGREE-II Instrument guideline to calculate the scores for each domain \[[@CR15]\].

We considered that when a CPG had a total score ≥ 70% it had adequate quality, we also used the same cutoff for each of the domains of the AGREE-II Instrument. This cutoff point was taken from a previous study that evaluated the quality of depression CPGs in children \[[@CR8]\]. Likewise, we considered that when a CPG had a score ≥ 70% in the third domain (rigor of development) of the AGREE-II Instrument, the CPG had an adequate rigor of development.

Results {#Sec8}
=======

We found twenty CPG for depression in adults published or updated between 2014 and 2018, of which thirteen performed systematic reviews to formulate their recommendations. Two CPGs were excluded from our study given that they were not available in full-text \[[@CR16], [@CR17]\], (See Additional file [2](#MOESM2){ref-type="media"}). Thus, we finally included eleven guidelines \[[@CR18]--[@CR28]\].

From the included guidelines, 2/11 included patients in the process of development of the CPG (one as part of the guideline development group \[NICE\], and 1/11 during the external validation \[GuiaSalud\]). Regarding how the development group reached the recommendations, 3/11 did not clearly state how recommendations were reached (Korea, RANZCP, USTF), 4/11 used expert consensus but did not specify the criteria evaluated (ACP, APA, VADoD, BAP), and 4/11 used a well-specified methodology (either: Grades of Recommendation, Assessment, Development, and Evaluation \[GRADE\], Scottish Intercollegiate Guidelines Network \[SIGN\], or Canadian Network for Mood and Anxiety Treatments \[CANMAT\]). All included guidelines specified the system they used for grading the strength of recommendations (Table [1](#Tab1){ref-type="table"}).Table 1Characteristics of the included CPGsAuthorsAbreviationYearCountryInvolvement of patients or their representativesMethodology used to reach recommendationsMethodology used for grading the strength of recommendationsUse of minimally important differenceCanadian Network for Mood and Anxiety Treatments (CANMAT)CANMAT2016CanadaNoCANMAT methodologyCANMATNoDepression Guideline Development Group (Acupuncture CPG)Acupuncture CPG2015ChinaNoGRADE methodologyGRADENoNational Collaborating Centre for Mental Health, National Institute for Health and Clinical Excellence (NICE)NICE2018United KingdomPart of the guideline development group. Does not explicitly state what they did.GRADE methodologyGRADEYes, they discuss the clinical importance of the effects, but a cut-off point is not clearly statedAgencia de Evaluación de Tecnologías Sanitarias de Galicia (GuiaSalud)GuiaSalud2014SpainExternal validation of guidelineSIGN methodologySIGNYes, they discuss the clinical importance of the effects, but a cut-off point is not clearly statedAmerican College of Physicians (ACP)ACP2016United States of AmericaNoExpert consensusACP's GRADE modificationYes, they discuss the clinical importance of the effects, but a cut-off point is not clearly statedAmerican Psychiatric Association (APA)APA2010United States of AmericaNoExpert consensusAPA (appears to be an expert consensus=NoRoyal Australian and New Zealand College of PsychiatristsRANZCP2018Australia New ZealandNoNot clearAdaptation of NHMRCNoUS Preventive Services Task Force Recommendation Statement (US-Task Force)USTF2016United States of AmericaNoNot clear.USPSTFYes, they discuss the clinical importance of the effects, cut-off points are stated (eg. PHQ-9)Management of Major Depressive Disorder Working Group (VA/DoD)VADoD2016United States of AmericaNoExpert consensusGRADENoKorean Guideline Development Team for DepressionKorea2014Republic of KoreaNoNot clearSIGN plus their modificationsNoBritish Association for Psychopharmacology (BAP)BAP2015United KingdomNoExpert consensusBAP criteriaYes. They state the cut-off points for each effect size measure.

The number of recommendations stated by each CPG varied between one and 199 recommendations. Three CPGs focused on one topic: the Acupuncture CPG \[[@CR19]\] that aimed to give recommendations regarding acupuncture treatment, the ACP guideline \[[@CR22]\] that aimed to determine the usage of pharmacological versus non-pharmacological treatment, and the US-Taskforce guideline \[[@CR25]\] that aimed to state how the screening of depression should be performed. The other eight CPGs addressed multiple topics: one on non-pharmacological treatment (Korea), two on treatment (APA, RANZCP) \[[@CR23], [@CR24]\] and five on diagnosis and treatment (CANMAT, NICE, GuiaSalud, VADoD, BAP). Of note, three CPGs issued consensus statements (either GCPs or consensus-based recommendations).

In general, 6/11 CPGs provided recommendations on screening (CANMAT, NICE, GuiaSalud, USTF, VADoD, BAP), 5/11 on diagnosis (CANMAT, NICE, GuiaSalud, VADoD, BAP), 8/11 on pharmacological treatment (of which, six established the first line of treatment \[CANMAT, GuiaSalud, APA, RANZCP, VADoD, BAP\], and five established first and the second line of treatment \[CANMAT, GuiaSalud, APA, RANZCP, BAP\]), 9/11 on non-pharmacological treatments (all of them discussed psychological treatment \[CANMAT, NICE, GuiaSalud, ACP, APA, RANZCP, VADoD, Korea, BAP\], seven provided recommendations on the use of electro-stimulation therapy \[CANMAT, NICE, GuiaSalud, APA, RANZCP, VADoD, BAP\], six on St. John's wort \[CANMAT, NICE, GuiaSalud, APA, VADoD, BAP\], and two on acupuncture \[CANMAT, Acupuncture CPG\]) (Table [2](#Tab2){ref-type="table"}).Table 2Topics and number of statements issued by each CPGThemeCANMATWHONICEGuiaSaludACPAPARANZCPUSTFVADoDKoreaBAPScreening1 R1 R4R 1 GCP1 R1 R3 R 1 GCPDiagnosis1 R4 R1 GCP1 R1 R 3 GCPPharmacological treatment Pharmacological treatment: general43 R35 R^b^8 R 5 GCP1 R^a^60 R^c^5 R 9 CBR^a^6 R115 R 15 GCP Pharmacological treatment: 1st line1 R3 R6 R3 R1 R7 R Pharmacological treatment: 2nd line1 R2 R3 R1 R7 RPsychological treatment Psychological treatment: general6 R7 R^b^2 R 1 GCP1 R^a^21 R^c^3 R 3 CBR^a^5 R7 R 3 GCP Psychological treatment: recommends at least one specific therapy14R15 R^b^4 R9 R3 R6 R5 R15 ROther non-pharmacological treatments Electro-stimulation9 R11 R4 R 2 GCP16 R7 R 2 CBR5 R20 R 6 GCP Acupuncture1 R12 R St. John's wort1 R1R1 R 1 GCP3 R1 R2 R Light therapy1 R1 R1 R6 R Exercise1 R1 R2 R1 R1 R3 R Yoga1 R Sleep deprivation1 R Others treatments10 R3 R4 ROther statements18 R35 R13 R 3 GCP89 R3 R 8 CBR6 R1 R9 R 22 GCPTotal of statements110 R12 R108 R43 R 14 GCP1 R^a^211 R^c^25 R 32 CBR1 R31 R7 R199 R 50 GCPR: recommendations, GCP: good clinical practice, CBR: consensus-based recommendation^a^ 01 recommendation included both pharmacological and psychological themes^b^ 02 recommendations included both pharmacological and psychological themes^c^ 06 recommendations included both pharmacological and psychological themes

To assess the quality of guidelines, we used the AGREE II instrument. The overall assessment score ranged from 53 to 87% (mean: 70.8%), and 4/11 guidelines had an overall assessment score ≥ 70% (NICE, ACP, USTF, VADoD). Regarding the third domain, scores ranged from 45 to 88% (mean: 62.9%), and 3/11 guidelines had a score ≥ 70% (NICE, ACP, VADoD) (Table [3](#Tab3){ref-type="table"}).Table 3Quality appraisal of CPGs for depression in adults, using the AGREE-II instrumentCPG (code)AGREE-II domainsQuality of the systematic reviews (Yes or No)1234567Overall assessmentMentions databases usedMentions search strategyList of included studies is availableMentioned risk of bias assessment as part of their methodologyCanadian Network for Mood and Anxiety Treatments (CANMAT)92%67%53%83%0%100%67%66%YesYesNoNoDepression Guideline Development Group (WHO)100%67%48%89%38%8%50%57%YesNoNoNoNational Collaborating Centre for Mental Health, National Institute for Health and Clinical Excellence (NICE)100%100%**85%**100%40%100%**83%**87%YesYesYesYesAgencia de Evaluación de Tecnologías Sanitarias de Galicia (GuiaSalud)100%92%60%94%96%100%67%87%YesNoYesYesAmerican College of Physicians (ACP)100%89%**88%**72%0%100%**83%**76%YesYesYesYesAmerican Psychiatric Association (APA)94%64%55%89%15%100%67%67%YesNoNoNoRoyal Australian and New Zealand\
College of Psychiatrists (RANZCP)100%81%59%100%8%100%67%74%YesNoNoNoUS Preventive Services Task Force Recommendation Statement (USTF)94%53%65%86%17%100%**83%**71%YesYesYesYesManagement of Major Depressive Disorder Working Group (VADoD)94%86%**78%**100%17%100%**83%**80%YesYesNoYesKorean Guideline Development Team for Depression (Korea)75%47%45%78%4%83%42%53%YesNoNoNoBritish Association for Psychopharmacology (BAP)83%56%55%78%13%83%58%61%YesNoNoYesFind in boldface values above 70% which represents adequate quality

Regarding the quality of the systematic review, 11/11 of the included CPGs stated what databases they used, 5/11 CPGs published their search strategy (CANMAT, NICE, ACP, USTF, VADoD), 4/11 CPGs presented the included studies (NICE, GuiaSalud, ACP, USTF), and 6/11 CPGs mentioned the risk of bias assessment as part of their methodology (NICE, GuiaSalud, ACP, USTF, VADoD, BAP) (Table [3](#Tab3){ref-type="table"}).

Discussion {#Sec9}
==========

Main findings {#Sec10}
-------------

This study explores the characteristics, scope, and quality of CPGs for depression in adults that based their recommendations on systematic reviews and were published between January 2014 and May 2018. We included eleven CPGs from seven countries on four continents, from which two reported the patient involvement in the design or validation of the CPGs, six provided recommendations on screening, five on diagnosis, eight on pharmacological treatment, nine on psychological treatment, nine on other non-pharmacological treatments. Regarding the quality assessment, 4/11 CPGs reached a score ≥ 70% in the overall assessment of the AGREE-II instrument, and 3/11 CPGs reached a score ≥ 70% in the rigor of development domain. In addition, only 5/11 CPGs shared their search strategy, while only 4/11 listed the selected studies they used to reach recommendations, and 7/11 CPGs did not clearly state which methodology they used to translate evidence into a recommendation.

Patient involvement {#Sec11}
-------------------

The involvement of patients or their representatives in the development of CPGs is considered important as it is supposed to complement scientific evidence to reach more acceptable and implementable recommendations \[[@CR29]\]. Thus, many guidelines development groups recommend its inclusion in every step through the development of CPGs, including the definition of the scope and objectives, the definition of the review questions, the developing of recommendations (sharing their preferences regarding the assessed interventions), and the review of the final version of the CPG \[[@CR30]\].

However, we found that 2/11 CPGs reported that patients had participated in the design or validation of the CPGs. This low patient involvement is similar to that found in other studies. One study that evaluated 62 Dutch guidelines assessed patients' participation in the development process through three items (patients' participation, identification of the patient's input in the CPG, and the emphasis of patients' participation in the individual patient level), and found that only 1/62 CPGs fulfilled satisfactorily these items \[[@CR31]\]. The CPG that fulfilled these criteria was the Dutch guideline for depression \[[@CR32]\]. Moreover, a study evaluated the patient involvement in guidelines in 101 organizations that publish CPGs in G-I-N North America and National Guideline Clearinghouse and found that only 8% of them require the patient or public involvement on guideline development groups, while 15% sometimes require it or describe it as optional \[[@CR33]\].

Quality of the CPGs {#Sec12}
-------------------

When focusing on the third domain of the AGREE II Instrument (rigor of development), few CPGs (3/11 = 27%) reached a score ≥ 70%. This is similar to a systematic review of CPGs for depression in children and youth that found that only 4/17 = 17.6% achieved a score ≥ 70% in this domain \[[@CR8]\]. Other studies have reached different results regarding the percentage of CPGs that achieved a score ≥ 70% in the third domain on the AGREE-II instrument. i.e.: 1/11 = 9.1% for Heparin-induced thrombocytopenia CPGs \[[@CR34]\], 15/115 = 13.0% for kidney transplantation CPGs \[[@CR35]\], 5/30 = 16.6% for fertility preservation in young women undergoing gonadotoxic treatment CPGs \[[@CR36]\], 6/17 = 35.3% for pediatric traumatic brain injury CPGs \[[@CR37]\], and 5/12 = 41.7% for treatments for oral cancer CPGs \[[@CR38]\].

Our results indicate that few of the CPGs achieve an adequate methodological quality, which could lead to recommendations that are not based on the best available evidence. This situation could be due to the fact that developing a high-quality CPG demands many financial resources, time, highly specialized personnel, and health system support \[[@CR39]--[@CR41]\]. In addition, some CPGs may fulfill an adequate rigor of development but attained a low score in the AGREE-II instrument because the development process was not adequately reported \[[@CR42]\]. To avoid this, the guideline development groups could apply AGREE-II or another instrument to verify the adequate reporting of their CPGs.

To state a recommendation, two basic steps are needed: the selection of evidence and the methodology used to translate evidence into a recommendation \[[@CR5]\]. We evaluated some characteristics in order to understand how these steps were performed.

Regarding the selection of evidence, only 5/11 CPGs shared their search strategy, while only 4/11 listed the selected studies they used to reach recommendations. Not sharing these information prevents the readers from adequately evaluating if there was any bias in the selection of evidence used to guide the recommendations, and prevents the replication and corroboration of the searches performed.

Regarding the methodology used to translate evidence into a recommendation, 7/11 CPGs did not clearly state the methodology used. A clearly defined methodology is necessary to understand what criteria were used and how the developing group judged each criterion to reach a recommendation. This allows users to understand how subjectivity and possible competing interest of the guideline developing group may have influenced on its recommendations, and help decide if recommendations can or should be implemented in their own settings \[[@CR43]\]. Inconsistent recommendations are not rare, as shown by a systematic review that assessed the recommendations stated in CPGs for depression treatment, which found inconsistencies in the recommendations for the second and third line of pharmacological treatment \[[@CR7]\]. For CPGs with inadequate methodology, it is necessary to evaluate the suitability of its use, and be careful when considering the implementation of its recommendations.

Limitations and strengths {#Sec13}
-------------------------

Our study is not free from limitations. We only collected guidelines published in English or Spanish, so our findings could not be representative of CPGs published in other languages. The CGPs quality was assessed using the AGREE-II instrument, based on the reporting of the CPGs, so guidelines with inadequate reporting could be classified as deficient, despite their actual quality. Lastly, there are not validated cut-off points for the AGREE-II instrument so the discrimination between CPGs with adequate and inadequate quality could be inaccurate.

However, to our knowledge, this is the first study that has evaluated the characteristics and quality of CPGs for depression in adults. This evaluation has some important strengths: we used a systematic search strategy involving eighteen databases to find available CPGs for depression in adults, we used the AGREE-II instrument that provides a standard methodology to critically appraise the quality of CPGs, and we performed independent appraisals by two researchers.

Conclusions {#Sec14}
===========

We found eleven CPGs for depression in adults that used systematic reviews to guide their recommendations. Only two CGPs reported patient involvement. Regarding the quality of these CPGs, only 4/11 CPGs reached a score ≥ 70% in the overall assessment of the AGREE-II instrument, and 3/11 CPGs reached a score ≥ 70% in the rigor of development domain. In addition, only 5/11 CPGs shared their search strategy, while only 4/11 listed the selected studies they used to reach recommendations, and 7/11 CPGs did not clearly state which methodology they used to translate evidence into a recommendation. These findings should be taken into account by stakeholders, CPGs developers, and CPGs users; when choosing CPGs, and interpreting and putting into practice their issued recommendations from CPGs for depression in adults.
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Additional file 1:Search strategies and results for CPGs for depression. We present the list of databases or CPG repositories, the search strategy and the results from the searches. (DOCX 14 kb) Additional file 2:Flowchart of selection of CPGs. We present the flowchart of how we selected the CPGs that were included in our study. (DOCX 21 kb)
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